39 Results for "

postmenopausal osteoporosis,

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "postmenopausal osteoporosis," in MCE Product Catalog:

186
186 Publications Verification
Cat. No.: HY-112879
CAS No.: 1334850-99-5
Purity:  99.19%
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
loading...
    loading...
186
186 Publications Verification
Cat. No.: HY-125944
CAS No.: 1569257-94-8
Purity:  98.03%
MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0037
CAS No.: 180916-16-9
Synonyms: CP-336156
Target:  

Estrogen Receptor/ERR

Research Areas:  

Inflammation/Immunology Cancer

Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0038
CAS No.: 190791-29-8
Synonyms: CP-336156 tartrate
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B0657A
CAS No.: 22560-50-5
Synonyms: Clodronate disodium salt
Target:  

Apoptosis

Research Areas:  

Metabolic Disease Cancer

Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10199A
CAS No.: 159634-47-6
Purity:  98.52%
Synonyms: MK-677 free base; MK-0677 free base
Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B0657
CAS No.: 10596-23-3
Synonyms: Clodronate
Target:  

Apoptosis

Research Areas:  

Metabolic Disease Cancer

Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107245
CAS No.: 164991-89-3
Purity:  99.51%
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15927
CAS No.: 2492-87-7
4-Nitrophenyl β-D-glucopyranoside is a chromogenic substrate for β-glucosidase. 4-Nitrophenyl β-D-glucopyranoside is converted to a colored product, p-nitrophenol that is easily detected spectrophotometrically at 405 nm when used in a β-glycosidase assay. 4-Nitrophenyl β-D-glucopyranoside is hydrolysed through intramolecular nucleophilic catalysis by the phosphate group in the 2-position. 4-Nitrophenyl β-D-glucopyranoside is promising for research of postmenopausal osteoporosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-169703
CAS No.: 1251839-15-2
Research Areas:  

Inflammation/Immunology

SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
loading...
    loading...
Cat. No.: HY-123047
CAS No.: 5630-53-5
Purity:  99.39%
Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
loading...
    loading...
Cat. No.: HY-121528
CAS No.: 39791-20-3
Purity:  98.93%
Synonyms: Nylestriol; EE3CPE
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology

Nilestriol is a estriol derivative, which inhibits osteoporosis on ovariectomized rats or postmenopausal women .
loading...
    loading...
Cat. No.: HY-P3075
CAS No.: 112540-82-6
Synonyms: pTHrP (1-34)
Research Areas:  

Inflammation/Immunology

pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study .
loading...
    loading...
Cat. No.: HY-N14323
CAS No.: 184877-64-3
Madindoline A is an orally active gp130 antagonist with a KD of 288 μM. Madindoline A inhibits IL-6- and IL-11-induced osteoclastogenesis, suppresses IL-6-stimulated serum amyloid A protein production, inhibits bone resorption and bone loss, and also inhibits IL-6- and IL-11-dependent cell line growth, as well as IL-6-dependent Stat3 tyrosine phosphorylation. Madindoline A is applicable for the research of hormone-dependent postmenopausal osteoporosis .
loading...
    loading...
Cat. No.: HY-116640
CAS No.: 4208-09-7
Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders .
loading...
    loading...
Cat. No.: HY-N2289
CAS No.: 135293-13-9
2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
loading...
    loading...
Cat. No.: HY-P0284
CAS No.: 162929-64-8
Target:  

MMP

Research Areas:  

Metabolic Disease

C-telopeptide is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD). C-telopeptide can be used in studies related to postmenopausal osteoporosis .
loading...
    loading...
Cat. No.: HY-P0284A
Target:  

MMP

Research Areas:  

Metabolic Disease

C-telopeptide TFA is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD). C-telopeptide TFA can be used in studies related to postmenopausal osteoporosis .
loading...
    loading...
Cat. No.: HY-B0631S
CAS No.: 1035437-39-8
Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
loading...
    loading...
Cat. No.: HY-N0943
CAS No.: 24808-04-6
(−)-Epiafzelechin is a COX-1 inhibitor with an IC50 of approximately 15 μM against COX-1 activity. (−)-Epiafzelechin also exhibits DPPH free radical scavenging activity, with an EC50 of 20.9 μM. (−)-Epiafzelechin promotes osteoblast differentiation by increasing ALP activity, ECM collagen content and Runx2 expression, while reducing the growth of osteoclast precursors and RANKL-induced TRAP activity, thereby regulating the bone remodeling process. (−)-Epiafzelechin alleviates ovariectomy-induced bone loss. (−)-Epiafzelechin can be used in studies related to bone remodeling, postmenopausal osteoporosis, inflammatory responses and oxidative stress .
loading...
    loading...